These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25450307)

  • 21. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
    Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
    Ulusoy A; Sahin G; Kirik D
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13159-64. PubMed ID: 20615977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
    Huot P
    J Neurol Sci; 2015 Apr; 351(1-2):9-12. PubMed ID: 25758471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular imaging of levodopa-induced dyskinesias.
    Niccolini F; Rocchi L; Politis M
    Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
    Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics and levodopa induced motor complications.
    Kalinderi K; Papaliagkas V; Fidani L
    Int J Neurosci; 2019 Apr; 129(4):384-392. PubMed ID: 30359152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K; Ferger B
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.